Navigation Links
The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference
Date:12/2/2009

COPENHAGEN, Dec. 2 /PRNewswire/ -- The world's first concept demonstration tires made with BioIsoprene technology, a breakthrough alternative to replace a petrochemically produced ingredient in the manufacture of synthetic rubber with renewable biomass, made their debut in Copenhagen, Denmark, this week. One tire will be on display at a lounge in the common departure area at the Copenhagen International Airport throughout December 21, while the other tire will make appearances at several special events during the United Nations Climate Change Conference in Copenhagen (COP 15) through December. The tires made with BioIsoprene are the result of a collaboration between Genencor, a division of Danisco, and Goodyear, one of the world's largest and most innovative tire companies.

"We are literally rolling out an important milestone in our collaboration with Goodyear on a breakthrough biochemical," says Tom Knutzen, CEO of Danisco. "BioIsoprene is an excellent example of Danisco's leadership in industrial biotechnology through our Genencor division. As we deliver enzymes to existing markets, we are also investing in future bio-innovations with extraordinary potential to address the world's most urgent business and environmental challenges."

"Goodyear's first concept tire manufactured with BioIsoprene shows the enormous progress we have made in using a bio-based alternative to the petroleum-derived raw material isoprene in our production process," says Jesse Roeck, Director, Global Materials Science at Goodyear. "The development of BioIsoprene could make Goodyear less dependent on oil-derived products. We share Genencor's vision of lessening industry impact on the environment by applying renewable raw materials in the supply chain."

Beyond tires, BioIsoprene offers vast potential in other applications, such as other rubber products and adhesives. The market for isoprene could reach up to 11 billion pounds per year by 2012. Genencor plans to bring the technology to pilot stage within two years, followed by commercial production.

"We're building advanced biorefineries of the future through strategic collaborations, such as our work with Goodyear and our joint venture DuPont Danisco Cellulosic Ethanol, as well as public-private partnerships," says Philippe Lavielle, Executive VP of Business Development for Genencor. "By joining forces with other industry leaders and leveraging our cutting edge biotech capabilities, we're able to accelerate development and deployment of breakthrough technologies like BioIsoprene."

Schedule of events for the world's first Goodyear concept tires made from BioIsoprene technology in Copenhagen, Denmark:

  • Through December 21 there will be a tire in the common departure area at The Copenhagen International Airport
  • December 12-13 there will be a tire at the Bright Green exhibition in the Danisco booth
  • December 17 a tire will be on display at the "Solutions of Industrial Biotechnology" Conference & Showcase, Confederation of Danish Industry (DI)
  • A tire will also be on display in the Danisco headquarters' reception area through December, please contact us for an appointment (jennifer.hutchins@danisco.com)

About Genencor

Genencor, a division of Danisco A/S, is a world leader in industrial biotechnology and a pioneer in enzyme innovation. Genencor improves process and product performance for a spectrum of industries, from biofuels and laundry detergents to animal nutrition and food. As part of a large global organization, Genencor has a manufacturing and distribution network that spans more than 40 countries. In collaboration with customers, technology leaders and other stakeholders, Genencor supplies competitive, biobased solutions. These innovations create value throughout the supply chain, from raw material to finished product.

SOURCE Genencor, a division of Danisco


'/>"/>
SOURCE Genencor, a division of Danisco
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
2. Celebrities and Notables From the Worlds of Film, Television, Music and Sports Join Lifetime Televisions 13th Annual Multi-Platform Stop Breast Cancer For Life Campaign
3. Maryland Science Center Unveils Anatomical Exhibition, Body Worlds 2, on Saturday, February 2
4. Tickets for Brand New Exhibition Body Worlds & The Mirror of Time on Sale 18 July
5. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
6. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
7. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
8. Genmab Announces 2007 First Half Year Results
9. Pharsight Achieves First License Sale for Public-Source Database
10. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
11. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 27, 2016 , ... Newly created 4Sight Medical Solutions ... the healthcare market. The company's primary focus is on new product introductions, to ... that are necessary to help companies efficiently bring their products to market. , ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... 2016  The Prostate Cancer Foundation (PCF) is pleased to announce ... cures for prostate cancer. Members of the Class of 2016 were selected from ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:6/22/2016)... On Monday, the Department of Homeland Security ... solutions for the Biometric Exit Program. The Request for ... (CBP), explains that CBP intends to add biometrics to ... United States , in order to deter visa ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/20/2016)... -- Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring announced that after exhaustive ... the final acceptance by all three (3) Department ... (MAS) installed. Furthermore, Securus will have contracts for ... October, 2016. MAS distinguishes between legitimate wireless device ...
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
Breaking Biology News(10 mins):